T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$2B |
| 2 |
Sea Limited
SE
|
+$1.34B |
| 3 |
Morgan Stanley
MS
|
+$1.23B |
| 4 |
Incyte
INCY
|
+$1.05B |
| 5 |
Ross Stores
ROST
|
+$968M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Boeing
BA
|
+$2.05B |
| 2 |
VMW
VMware, Inc
VMW
|
+$1.5B |
| 3 |
Visa
V
|
+$1.16B |
| 4 |
JPMorgan Chase
JPM
|
+$1.13B |
| 5 |
Meta Platforms (Facebook)
META
|
+$1.12B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 25.01% |
| 2 | Healthcare | 17.6% |
| 3 | Consumer Discretionary | 14.37% |
| 4 | Financials | 11.89% |
| 5 | Communication Services | 10.75% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
501
Agios Pharmaceuticals
AGIO
$2B
| $175M | 0.02% |
3,277,313
+581,583
| +22% | +$26.9M |
|
502
Cavco Industries
CVCO
$4.67B
| $175M | 0.02% |
907,087
-32,773
| -3% | -$5.37M |
|
503
Xencor
XNCR
$1.71B
| $175M | 0.02% |
5,399,495
+237,138
| +5% | +$7.27M |
|
|
CUB
504
DELISTED
Cubic Corporation
CUB
| $175M | 0.02% |
3,639,524
-50,278
| -1% | -$2.04M |
|
505
Gen Digital
GEN
$17.7B
| $173M | 0.02% |
8,744,236
-2,997,074
| -26% | -$61M |
|
|
CVET
506
DELISTED
Covetrus, Inc. Common Stock
CVET
| $172M | 0.02% |
9,641,458
-1,236,251
| -11% | -$16.2M |
|
|
WRK
507
DELISTED
WestRock Company
WRK
| $172M | 0.02% |
6,100,034
+2,469,782
| +68% | +$70.2M |
|
508
Lockheed Martin
LMT
$138B
| $171M | 0.02% |
467,416
-36,618
| -7% | -$13.8M |
|
509
McCormick & Company Non-Voting
MKC
$14.6B
| $170M | 0.02% |
1,897,398
-74,508
| -4% | -$6.14M |
|
510
BP
BP
$110B
| $170M | 0.02% |
7,279,712
+36,970
| +0.5% | +$887K |
|
511
Ally Financial
ALLY
$13.6B
| $169M | 0.02% |
8,519,423
+1,978,122
| +30% | +$33.7M |
|
512
Franklin Resources
BEN
$17.2B
| $168M | 0.02% |
8,027,417
-4,196,576
| -34% | -$79.2M |
|
513
Nomad Foods
NOMD
$1.68B
| $168M | 0.02% |
7,828,659
-580,544
| -7% | -$12.1M |
|
514
Kraft Heinz
KHC
$30.1B
| $167M | 0.02% |
5,235,382
+310,895
| +6% | +$9.33M |
|
|
KYNB
515
Kyntra Bio
KYNB
$28.5M
| $167M | 0.02% |
164,685
+82,606
| +101% | +$76.7M |
|
516
Allogene Therapeutics
ALLO
$683M
| $162M | 0.02% |
3,790,786
+1,586,252
| +72% | +$57.4M |
|
517
Rexford Industrial Realty
REXR
$8.12B
| $161M | 0.02% |
3,897,123
+42,110
| +1% | +$1.69M |
|
518
Bausch Health
BHC
$2.37B
| $161M | 0.02% |
8,784,546
+6,269,935
| +249% | +$110M |
|
|
ATVI
519
DELISTED
Activision Blizzard
ATVI
| $161M | 0.02% |
2,115,414
+336,739
| +19% | +$23.5M |
|
520
Allegion
ALLE
$14.2B
| $160M | 0.02% |
1,570,068
-160,548
| -9% | -$15.8M |
|
521
SLM Corp
SLM
$5.22B
| $160M | 0.02% |
22,815,311
-780,327
| -3% | -$5.83M |
|
|
HR
522
DELISTED
Healthcare Realty Trust Incorporated
HR
| $160M | 0.02% |
5,471,898
-1,049,541
| -16% | -$31.4M |
|
523
Simon Property Group
SPG
$71.7B
| $160M | 0.02% |
2,343,165
-295,086
| -11% | -$18.5M |
|
524
Tapestry
TPR
$25.9B
| $160M | 0.02% |
12,020,059
-2,413,942
| -17% | -$34.3M |
|
525
Target
TGT
$70.6B
| $160M | 0.02% |
1,330,226
+297,997
| +29% | +$34M |
|
Similar funds
T. Rowe Price Associates's Q2 2020 Portfolio in Review
As of Q2 2020, T. Rowe Price Associates held 2,591 positions worth $795B, up 26% from $632B the previous quarter. Its ten largest holdings account for 25% of the portfolio.
T. Rowe Price Associates's Q2 2020 filing shows 79 new, 1,096 increased, 1,255 reduced and 100 closed positions. Its largest new stake was Vroom Inc: 200,362 shares worth $797M. The largest sale was Boeing, an estimated $2.05B.
By sector, the portfolio is most concentrated in Technology at 25% of assets, up from 23% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q2 2020 buy was Vroom Inc: 200,362 shares worth $797M.
- T. Rowe Price Associates added most to Microsoft in Q2 2020, an estimated $2B increase.
- T. Rowe Price Associates's biggest Q2 2020 reduction was Boeing, cutting an estimated $2.05B.
- T. Rowe Price Associates fully exited Raytheon Company in Q2 2020, selling an estimated $1.01B.
- T. Rowe Price Associates's ten largest holdings make up 25% of its $795B portfolio in Q2 2020.
- T. Rowe Price Associates opened 79 new positions and closed 100 in Q2 2020.
- T. Rowe Price Associates's portfolio value rose 26% quarter-over-quarter to $795B.
Based on T. Rowe Price Associates's 13F filing for Q2 2020, filed 14 Aug 2020.